A Study of the Effectiveness of an HIV Vaccine (ALVAC vCP205) to Boost Immune Functions in HIV-Negative Volunteers Who Have Already Received an HIV Vaccine

NCT00001136 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

60

Enrollment

NIH

Sponsor class

Conditions

HIV Infections
HIV Seronegativity

Interventions

BIOLOGICAL: ALVAC-HIV MN120TMG (vCP205)

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)